for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkermes Plc

ALKS.OQ

現在値

30.85USD

変化

0.19(+0.62%)

出来高

259,723

本日のレンジ

30.49

 - 

30.91

52週レンジ

15.35

 - 

33.00

∙ 約20分前の相場を表示しています。

適時開示

Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa For The Treatment Of Mucosal Melanoma

Aug 2 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES RECEIVES FDA FAST TRACK DESIGNATION FOR NEMVALEUKIN ALFA FOR THE TREATMENT OF MUCOSAL MELANOMA.

Alkermes Q2 Revenue Rose 23 Percent To 303.7 Million USD

July 28 (Reuters) - Alkermes Plc <ALKS.O>::Q2 REVENUE ROSE 23 PERCENT TO 303.7 MILLION USD.Q2 DILUTED EARNINGS PER SHARE 0.01 USD.QTRLY NON-GAAP DILUTED EARNINGS PER SHARE OF $0.30.SEES TOTAL REVENUE$1,145 MILLION - $1,185 MILLION FOR 2021.SEES GAAP NET LOSS PER SHARE $0.37 - $0.56 FOR 2021.SEES NON-GAAP DILUTED EPS $0.52 - $0.70 FOR 2021.FY2021 EARNINGS PER SHARE VIEW $0.49, REVENUE VIEW $1.14 BILLION -- REFINITIV IBES DATA.

Alkermes Announces FDA Approval Of Lybalvi For The Treatment Of Schizophrenia And Bipolar I Disorder

June 1 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES FDA APPROVAL OF LYBALVI™ FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR I DISORDER.ALKERMES PLC - COMMERCIAL LAUNCH PLANNED FOR Q4 2021.ALKERMES PLC - NEW ORAL MEDICATION OFFERS ESTABLISHED ANTIPSYCHOTIC EFFICACY OF OLANZAPINE WITH LESS WEIGHT GAIN.

Alkermes Posts Q1 Non-GAAP Earnings Per Share $0.11

April 28 (Reuters) - Alkermes Plc <ALKS.O>::REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.11.Q1 REVENUE $251.4 MILLION.Q1 GAAP LOSS PER SHARE $0.14.SAYS FINANCIAL EXPECTATIONS FOR 2021 REITERATED.

Alkermes Announces FDA Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma

March 11 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR NEMVALEUKIN ALFA FOR TREATMENT OF MUCOSAL MELANOMA.

Alkermes Posts Q4 Adj Earnings Per Share $0.10

Feb 11 (Reuters) - Alkermes Plc <ALKS.O>::REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DEC. 31, 2020 AND PROVIDES FINANCIAL EXPECTATIONS FOR 2021.Q4 NON-GAAP EARNINGS PER SHARE $0.10.Q4 REVENUE $280 MILLION.Q4 GAAP LOSS PER SHARE $0.27.SEES 2021 TOTAL REVENUE $1.10 BILLION - $1.17 BILLION.SEES 2021 GAAP NET LOSS PER SHARE $0.53-$0.78.SEES NON-GAAP DILUTED EPS $0.37 - $0.62.FY2021 EARNINGS PER SHARE VIEW $0.52, REVENUE VIEW $1.12 BILLION -- REFINITIV IBES DATA.

Alkermes Announces Updates To Executive Leadership Team

Jan 6 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES UPDATES TO EXECUTIVE LEADERSHIP TEAM.ALKERMES PLC - IAIN M. BROWN NAMED CHIEF FINANCIAL OFFICER.

FDA Accepts Alkermes' Resubmission Of New Drug Application For ALKS 3831

Dec 29 (Reuters) - Alkermes Plc <ALKS.O>::FDA ACCEPTS ALKERMES' RESUBMISSION OF NEW DRUG APPLICATION FOR ALKS 3831.ALKERMES PLC - FDA SETS PDUFA TARGET ACTION DATE OF JUNE 1, 2021.

Alkermes Receives FDA Complete Response Letter Related To ALKS 3831 Manufacturing Records Review

Nov 17 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES RECEIVES FDA COMPLETE RESPONSE LETTER RELATED TO ALKS 3831 MANUFACTURING RECORDS REVIEW.ALKERMES PLC - NO CLINICAL EFFICACY OR SAFETY ISSUES RAISED AND NO FURTHER STUDIES REQUIRED BY FDA TO SUPPORT APPROVAL.ALKERMES PLC -.ALKERMES PLC - PLANS TO ENGAGE WITH FDA TOWARD EXPEDITIOUS RESOLUTION OF OUTSTANDING ITEMS.ALKERMES - THROUGHOUT DEVELOPMENT, ALKS 3831 DEMONSTRATED CONSISTENT ANTIPSYCHOTIC EFFICACY, SAFETY, TOLERABILITY PROFILE IN SCHIZOPHRENIA PATIENTS.ALKERMES - FDA STATED RESOLUTION OF CERTAIN CONDITIONS FOR TABLET COATING PROCESS AT WILMINGTON, OH FACILITY REQUIRED BEFORE ALKS 3831 MAY BE APPROVED.

Alkermes PLC Reports Q3 Adjusted Earnings Per Share $0.26

Oct 29 (Reuters) - Alkermes Plc <ALKS.O>::REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND RAISES 2020 FINANCIAL EXPECTATIONS.Q3 NON-GAAP EARNINGS PER SHARE $0.26.Q3 REVENUE $265 MILLION VERSUS REFINITIV IBES ESTIMATE OF $238.5 MILLION.Q3 GAAP EARNINGS PER SHARE $0.00.Q3 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.SEES FY TOTAL REVENUE $1,010 MILLION - $1,035 MILLION.SEES FY NON-GAAP DILUTED EPS $0.31 - $0.43.SEES FY GAAP NET LOSS PER SHARE 60 CENTS - 72 CENTS.FY2020 EARNINGS PER SHARE VIEW $0.10, REVENUE VIEW $982.5 MILLION -- REFINITIV IBES DATA.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up